Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Tickers in this article: ACAD ANF BBY BIIB CBRL CELG COST DKS DRTX DSW ENB FL GILD GME HD HPQ JCI KEX LGF LOW LRCX M NKE ORCL PANW PLAB REGN ROST SAP TIF TIVO TJX TYCO UA WDAY WEN WMT WSM
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- The Federal Reserve is not going to get in the way of a good holiday season, Jim Cramer told his "Mad Money" viewers Friday.

That's why Cramer said he'd use any weakness in the market next Wednesday to buy up some of the great stocks that will be put on sale.

Cramer expects the market to weaken on Wednesday ahead of of Thankgiving as it digests the latest unemployment data, durable goods and consumer sentiment numbers. That would be a great time to buy some of the stocks that will be reporting earlier next week, such as Workday and Palo Alto Networks , both of which report on Monday.

Cramer said the highly valued Workday could get crushed on anything less that a "beat and raise" quarter, but this cloud-based human resource management company is a buy on any weakness. Palo Alto, he said, is also highly valued, but also worth the expense.

Tuesday brings earnings from Hewlett-Packard , a stock Cramer said he's liking more now that Dell has none private. He also expects solid results from Tiffany , Cracker Barrel and DSW , three stocks that are up 41%, 41% and 81% respectively for the year.

Also on Tuesday, TiVo , a stock that's also become a great value.

Cramer said he'd use weakness on Wednesday to picking any of these names.

Riding High Again

The four horsemen of biotech ride again, Cramer told viewers. The stocks of Gilead Sciences , Celgene , Biogen Idec and Regeneron will be the anointed four going into the close of the year.

Cramer said love for the biotechs comes and goes, fizzling late this summer after a rash of red-hot IPOs. But over the past few weeks, the biotechs have once again come into fashion and been red-hot commodities for investors.

Cramer said there's three reasons for the move. First is the continued economic growth, followed by growth overseas and, finally, a host of new drug approvals. All three of these factors will continue these stocks on their current trajectory. Both Gilead and Celgene have seen approvals in the European Union strengthen their stocks while Biogen saw its shares jump $20 just today on a new approval.